The estimated Net Worth of John A Iii Herrmann is at least $6.7 Milione dollars as of 14 December 2023. Mr. Herrmann owns over 2,100 units of Novavax stock worth over $171,237 and over the last 10 years he sold NVAX stock worth over $5,173,360. In addition, he makes $1,353,420 as Executive Vice President e Chief Legal Officer at Novavax.
John has made over 42 trades of the Novavax stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 2,100 units of NVAX stock worth $25,809 on 14 December 2023.
The largest trade he's ever made was exercising 46,242 units of Novavax stock on 18 August 2020 worth over $2,488,744. On average, John trades about 5,987 units every 61 days since 2014. As of 14 December 2023 he still owns at least 13,933 units of Novavax stock.
You can see the complete history of Mr. Herrmann stock trades at the bottom of the page.
John A. Herrmann III serves as Executive Vice President, Chief Legal Officer of the Company. He has served as Senior Vice President, General Counsel and Corporate Secretary since June 2014. He previously served as the Company’s Vice President, General Counsel and Corporate Secretary from March 2012 to June 2014, and its Executive Director, Legal Affairs and Corporate Secretary from April 2010 to March 2012. Prior to joining the Company, Mr. Herrmann was General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic before it became Ore Pharmaceuticals. Mr. Herrmann worked as Senior Counsel for Celera Genomics following his position as Senior Corporate Counsel at Baxter Healthcare in its Renal Division. Mr. Herrmann received a B.A. in political science and history from Brown University and a J.D. from the University of Illinois.
As the Executive Vice President e Chief Legal Officer of Novavax, the total compensation of John Herrmann at Novavax is $1,353,420. There are 3 executives at Novavax getting paid more, with Stanley Erck having the highest compensation of $2,438,560.
John Herrmann is 54, he's been the Executive Vice President e Chief Legal Officer of Novavax since 2020. There are 16 older and 4 younger executives at Novavax. The oldest executive at Novavax, Inc. is Michael McManus, 77, who is the Independent Director.
John's mailing address filed with the SEC is C/O NOVAVAX, INC., 21 FIRSTFIELD ROAD, GAITHERSBURG, MD, 20878.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi e Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: